Overview
Lobbying Costs
1,375,000€
Financial year: Jan 2020 - Dec 2020
Lobbyists (Full time equivalent)
4.5 Fte (9)
Lobbyists with EP accreditation
0
High-level Commission meetings
5
Lobbying Costs over the years
-
Info
F. Hoffmann-La Roche Ltd (Roche)
EU Transparency Register
18940431725-51 First registered on 20 May 2009
Goals / Remit
Roche is a global pioneer in pharmaceuticals and diagnostics making it a leader in personalised healthcare to advance science to improve people’s lives.
Roche is the world’s largest biotech company, with truly differentiated medicines, as well as, the world leader in in vitro and tissue-based cancer diagnostics.
Since 1896, Roche searches for better ways to prevent, diagnose and treat diseases and improves patient access to innovation. More than 30 medicines developed by Roche are included in the WHO Model Lists of Essential Medicines. For the 12th consecutive year, Roche was ranked one of the most sustainable companies by the Dow Jones Sustainability Indices.
Roche employs over 101,000 people in over 100 countries. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the US, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.Main EU files targeted
Interactions (direct contacts) with EU Institutions relating to legislation and implementation of EU regulation at national level, e.g. Access to Medicines, EU Pharmaceutical Strategy, Incentives, Health Technology Assessment, In-Vitro Diagnostic / Medical Devices Regulations, General Data Protection Regulation, Shaping Europe’s Digital Strategy, Horizon Europe, Pharmaceuticals in the Environment, Shortages, Orphan Medicinal Products / Pediatric Regulations, European Green Deal, Cross-border Healthcare, European Health Union.
Our expertise and knowledge enables us to contribute convincing arguments on policy topics that are of high priority to us, such as:
- How to provide patients with timely and safe access to medicines and diagnostics.
- How to create a culture which fosters innovation, e.g. by granting intellectual property (IP) protection.
- How to get a fair value for innovative products, devices and services.
- How to use innovative approaches to personalised healthcare. This includes making use of big data while protecting data privacy.
- Provide input to EU Institutions’ open consultations, including participation in events sponsored by EU Institutions.
- Improve patient safety and strengthen disease prevention in Europe.
- Provide coverage and reimbursement that reward innovation.
- Increase Europe's competitiveness as a location for Research and Development investment.
- How to develop innovative diabetes technologies and services for patients.Address
Head Office
Grenzacherstrasse, 124
Basel 4070
SWITZERLAND -
People
Total lobbyists declared
9
Employment time Lobbyists 100% 1 75% 2 50% 2 25% 4 Lobbyists (Full time equivalent)
4.5
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
0 accreditations were / are live (in bold) for the selected state of 08 Apr 2021
Name Start date End Date Ludovic LACAINE 11 May 2023 10 May 2024 Luc Etienne FAUQUEX 11 May 2023 10 May 2024 Luc-Etienne Fauquex 24 Apr 2024 23 Apr 2026 Ms Nathalie STIEGER 15 Aug 2019 01 Sep 2020 Ms Nathalie STIEGER 06 Sep 2017 02 Sep 2018 Ms Nathalie STIEGER 22 Aug 2016 05 Aug 2017 Ms Christiane Landsberg 29 Jul 2015 28 Jul 2016 Ms Nathalie STIEGER 21 Jun 2015 18 Jun 2016 Ms Nathalie STIEGER 19 Jun 2014 17 Jun 2015 Ms Sabine Atzor 06 Aug 2014 04 Aug 2015 Mrs Sabine Atzor 06 Aug 2014 27 Jan 2015 Mrs Nathalie STIEGER 19 Jun 2014 27 Jan 2015 Mrs Sabine Atzor 09 Aug 2013 06 Aug 2014 Mrs Nathalie STIEGER 16 Apr 2013 11 Apr 2014 Mrs Nathalie STIEGER 10 Feb 2012 01 Mar 2013 Complementary Information
EU-related activities are conducted from the headquarters in Basel, as Roche does not have a public affairs office in Brussels.
The above information follows and is consistent with the guidance provided by the European Federation of Pharmaceutical Industries and Associations (EFPIA).Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
Roche is a member of EFPIA, MedTech Europe, DigitalEurope and national pharmaceutical and diagnostics associations, EAPM, AMISA2.
Member organisations
None declared
-
Financial Data
Closed financial year
Jan 2020 - Dec 2020
Lobbying costs for closed financial year
1,375,000€
Other financial info
All estimates for this submission have been done following the Transparency Register Implementation Guidelines, and are consistent with the guidance provided by the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Roche would like to indicate that all entries have been made in line with the greatest possible transparency and are periodically being updated as required.
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
Future Healthcare Index (Supported by Roche; https://futureproofinghealthcare.com/): Everyone should have equal access to healthcare. Meaningful conversations and sharing best practice will help to achieve this. The website is an interactive tool showcasing insights and data from the FutureProofing Healthcare Indices to support this dialogue. Two indices have been created so that accredited third-party data can be efficiently and effectively explored. The Sustainability Index provides a holistic snapshot of what healthcare systems across the EU look like today. The objective of the indices is to start a collaborative future-focused conversation on the sustainability of healthcare. In order to drive this conversation, a steering panel of healthcare experts has rigorously guided the building of the indices to make the final tool as neutral, relevant and wide-reaching as possible.
Other activities
At European level, Roche is committed to participating in a constructive, transparent, sincere and responsible dialogue with other stakeholders.
Meetings
Meetings
5 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 15 Apr 2024 Location Brussels Subject Meeting WEF CEO Action Group for the European Green Deal Cabinet Cabinet of Vice-President Maroš Šefčovič Attending - Maroš Šefčovič (Executive Vice-President)
- Virginie Battu-henriksson (Cabinet member)
Other Lobbyists -
Date 18 Jan 2023 Location Davos, Switzerland Subject EU Innovation Agenda Cabinet Cabinet of Commissioner Mariya Gabriel Portfolio Digital Economy and Society Attending - Mariya Gabriel (Commissioner)
-
Date 18 Jan 2023 Location Davos, Switzerland Subject EU Innovation Agenda Cabinet Cabinet of Commissioner Mariya Gabriel Portfolio Innovation and Youth Attending - Mariya Gabriel (Commissioner)
-
Date 12 Jul 2022 Location video-call Subject Pharmaceutical directive Cabinet Cabinet of Executive Vice-President Valdis Dombrovskis Portfolio An Economy that Works for People Attending - Caroline Boeshertz (Cabinet member)
-
Date 13 Oct 2017 Location Mannheim Subject digital policy Cabinet Cabinet of Vice-President Günther Oettinger Portfolio Budget & Human Resources Attending - Günther Oettinger (Commissioner)